Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | DPP4 | P27487 | 7/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
| ▸ | CNKSR1 | Q969H4 | 1/20 | 0.33 |
| ▸ | TTR | P02766 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | GALK1 | P51570 | 1/20 | 0.32 |
| ▸ | CCR6 | P51684 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30607053 | 1.00 | NPSR1 (0.38) | NPSR1DPP4CYP3A4ALDH1A1TDP1 | |
| SCHEMBL440648 | 1.00 | NPSR1 (0.38) | NPSR1DPP4CYP3A4ALDH1A1TDP1 | |
| SCHEMBL27791252 | 0.90 | MGAM (0.33) | NPSR1DPP4CYP3A4ALDH1A1TDP1 | |
| SCHEMBL18752139 | 0.86 | ATM (0.41) | NPSR1CYP3A4TDP1MAPTRAB9A | |
| SCHEMBL29738305 | 0.85 | DPP4 (0.41) | DPP4DPP9RORCMMP1MMP2 | |
| SCHEMBL2861837 | 0.85 | DPP4 (0.41) | DPP4DPP9RORCMMP1MMP2 | |
| SCHEMBL742800 | 0.85 | DPP4 (0.41) | DPP4DPP9RORCMMP1MMP2 | |
| SCHEMBL3801151 | 0.84 | MAPT (0.39) | DPP4CYP3A4ALDH1A1KCNH2KDM4E | |
| SCHEMBL3801146 | 0.84 | MAPT (0.39) | DPP4CYP3A4ALDH1A1KCNH2KDM4E | |
| SCHEMBL19500636 | 0.80 | HCAR2 (0.44) | DPP4ALDH1A1TDP1TTRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2404921-B1 | SALTS OF TETRAHYDROIMIDAZO[1,5-a]PYRAZINE DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO (CN) | 2017-11-22 | — | — | EP | disclosed |
| EP-2404921-B1 | SALTS OF TETRAHYDROIMIDAZO[1,5-a]PYRAZINE DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO (CN) | 2017-11-22 | — | — | EP | disclosed |
| EP-2230241-B1 | TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES, PREPARATION METHODS AND MEDICAL USES THEREOF | JIANGSU HENGRUI MEDICINE CO (CN) | 2014-11-26 | — | — | EP | disclosed |
| US-8518946-B2 | Salts of (R)-7-[3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-trifluoromethyl-5,6,7,8-tetrahydroimidazo[1,5-a] pyrazine-1-carboxylic acid, preparation method and medical use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2013-08-27 | — | — | US | disclosed |
| US-8518946-B2 | Salts of (R)-7-[3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-trifluoromethyl-5,6,7,8-tetrahydroimidazo[1,5-a] pyrazine-1-carboxylic acid, preparation method and medical use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2013-08-27 | — | — | US | disclosed |
| US-8518946-B2 | Salts of (R)-7-[3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-trifluoromethyl-5,6,7,8-tetrahydroimidazo[1,5-a] pyrazine-1-carboxylic acid, preparation method and medical use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2013-08-27 | — | — | US | disclosed |
| US-8513411-B2 | Tetrahydro-imidazo[1,5-α] pyrazine derivatives, preparation process and medicinal use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2013-08-20 | — | — | US | disclosed |
| US-8513411-B2 | Tetrahydro-imidazo[1,5-α] pyrazine derivatives, preparation process and medicinal use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2013-08-20 | — | — | US | disclosed |
| US-8513411-B2 | Tetrahydro-imidazo[1,5-α] pyrazine derivatives, preparation process and medicinal use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2013-08-20 | — | — | US | disclosed |
| US-20120220766-A1 | TETRAHYDRO-IMIDAZO[1,5-alpha] PYRAZINE DERIVATIVES, PREPERATION PROCESS AND MEDICINAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2012-08-30 | — | — | US | disclosed |
| US-20100273786-A1 | TETRAHYDRO-IMIDAZ0[1,5-A]PYRAZINE DERIVATIVES, PREPARATION PROCESS AND MEDICINAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2010-10-28 | — | — | US | disclosed |
| US-20100273786-A1 | TETRAHYDRO-IMIDAZ0[1,5-A]PYRAZINE DERIVATIVES, PREPARATION PROCESS AND MEDICINAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2010-10-28 | — | — | US | disclosed |
| US-20100273786-A1 | TETRAHYDRO-IMIDAZ0[1,5-A]PYRAZINE DERIVATIVES, PREPARATION PROCESS AND MEDICINAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2010-10-28 | — | — | US | disclosed |
| EP-2230241-A1 | TETRAHYDRO-IMIDAZOÝ1,5-A¨PYRAZINE DERIVATIVES, PREPARATION METHODS AND MEDICAL USES THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2010-09-22 | — | — | EP | disclosed |
| CN-101641360-A | Piperazine derivatives, preparation method and medical application thereof | SHANGHAI HENGRUI PHARM CO LTD | 2010-02-03 | — | — | CN | disclosed |
| US-20090192326-A1 | Preparation of sitagliptin intermediate | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-07-30 | — | — | US | disclosed |
| US-20090192326-A1 | Preparation of sitagliptin intermediate | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-07-30 | — | — | US | disclosed |
| US-20090192326-A1 | Preparation of sitagliptin intermediate | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-07-30 | — | — | US | disclosed |
| WO-2009064476-A1 | PREPARATION OF SITAGLIPTIN INTERMEDIATE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-05-22 | — | — | WO | disclosed |
| WO-2009064476-A1 | PREPARATION OF SITAGLIPTIN INTERMEDIATE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192326-A1 | Preparation of sitagliptin intermediate | DPP4, DPP7, DPP3 | NPSR1 2488/4885DPP4 1/4885CYP3A4 214/4885 |
| US-20120220766-A1 | TETRAHYDRO-IMIDAZO[1,5-alpha] PYRAZINE DERIVATIVES, PREPERATION PROCESS AND MEDICINAL USE THEREOF | DPP4, DPP3, DPP7 | NPSR1 1188/4885DPP4 1/4885CYP3A4 17/4885 |
| US-20100273786-A1 | TETRAHYDRO-IMIDAZ0[1,5-A]PYRAZINE DERIVATIVES, PREPARATION PROCESS AND MEDICINAL USE THEREOF | DPP4, DPP7, DPP3 | NPSR1 2304/4885DPP4 1/4885CYP3A4 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.